MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+1.4%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (1956)	4/2/2008 6:18:01 AM
From: Icebrg	Read Replies (1) of 2240

Yes, it was a very disappointing result. Pfizer's trial design was most probably "not optimal", as they were comparing chemotherapy (with immediate effects) with anti-CTLA-4 (with delayed effects). As we have learned over the last year it may well take considerable time before the anti-CTLA-4 effects kicks in. Sometimes that happens only after progression. MEDX and BMY have been more conservative in their designs (I hope), as they are using ipilimumab plus chemo against chemo alone in the first line setting and ipilimumab against nothing for the second-line trials. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next